Novartis moving 120 Alcon jobs to Massachusetts

Posted Tuesday, Apr. 09, 2013  comments  Print Reprints

Have more to add? News tip? Tell us

FORT WORTH -- Swiss pharmaceutical giant Novartis said Tuesday that it is consolidating its U.S.-based eye disease research projects in Cambridge, Mass., and closing the Novartis Institutes for BioMedical Research group on its Alcon Labs campus in Fort Worth.

About 120 employees in Fort Worth were told that their jobs will end June 11, said Dave Jackson, an Alcon spokesman. They will be allowed to apply for jobs in Cambridge and for other Alcon positions, he said.

"Alcon's research and development operations in Fort Worth, focused on pharmaceutical development and formulation as well as medical device research and development, will continue to operate with its full workforce of approximately 950 associates," Jackson said.

The Novartis Institutes for BioMedical Research has 1,600 scientists in Cambridge, he said. Researchers who do not move to Cambridge or do not apply for jobs in Fort Worth will be eligible for a severance package, Jackson said.

Novartis acquired Alcon, a producer of ophthalmic surgical products and pharmaceuticals, in 2011. After the purchase, Novartis said it was expanding its facilities in south Fort Worth with a Finance Service Center for the company's North American operation, as well as integrating its Atlanta-based Ciba Vision and Novartis Ophthalmic units into Alcon's operations.

The company added hundreds of jobs and now has 4,800 employees in Fort Worth, Jackson said.

The City Council established a reinvestment zone for Alcon's campus off Interstate 35W near Interstate 20 and granted an 80 percent tax abatement on the incremental real and personal property taxes for 10 years.

Sandra Baker, 817-390-7727

Twitter: @SandraBakerFWST

Looking for comments?

We welcome your comments on this story, but please be civil. Do not use profanity, hate speech, threats, personal abuse or any device to draw undue attention. Our policy requires those wishing to post here to use their real identity.

Our commenting policy | Facebook commenting FAQ | Why Facebook?